Muhammad Ali, MD
Pulmonary Disease · North Little Rock, ARNPI 1780971192
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,911 of the $10,873 with a category attached, or 72.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 23.9%. 2025 is the largest year on record at $4,885, more than ten times the $123 reported in 2019.
Across 408 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- GSK$1K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Sanofi$774
- United Therapeutics Corporation$371
- plus $3K from 28 others
Across 2 payments — averaging $3278.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$6K
- Eli Lilly$257
What the payments were for
- Food & beverage$7,91173%
- Education$2,96227%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $2,603 |
| GSK | 93 | $1,354 |
| AstraZeneca | 65 | $1,256 |
| Boehringer Ingelheim | 51 | $1,047 |
| Sanofi | 30 | $774 |
| United Therapeutics Corporation | 14 | $371 |
| Regeneron Healthcare Solutions, Inc. | 15 | $370 |
| Mallinckrodt Hospital Products Inc. | 11 | $346 |
| Sanofi-aventis U.S. LLC | 4 | $340 |
| Baxter Healthcare | 15 | $306 |
| Mylan Specialty L.p. | 14 | $253 |
| Grifols USA, LLC | 10 | $229 |
| Actelion Pharmaceuticals US, Inc. | 7 | $161 |
| Genentech USA, Inc. | 8 | $142 |
| Merck | 6 | $126 |
| Novartis | 1 | $123 |
| Philips North America LLC | 6 | $113 |
| Pfizer | 6 | $113 |
| Verona Pharma, Inc. | 5 | $102 |
| Electromed, Inc. | 10 | $100 |
| Amgen | 5 | $99 |
| AbbVie | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Viatris Specialty LLC | 3 | $72 |
| Johnson & Johnson | 4 | $66 |
| Insmed, Inc. | 3 | $55 |
| Nevro Corp. | 2 | $31 |
| Pulmonx Corporation | 1 | $29 |
| Melinta Therapeutics, LLC | 1 | $27 |
| Vapotherm Inc | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,500
- COSENTYX$123
How this compares
$10,873 in reported general payments places this provider in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $113,843 |
| Dupixent PenDupilumab | 17 | $65,367 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $35,780 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $34,562 |
| Spiriva RespimatTiotropium Bromide | 44 | $23,397 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $19,838 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $15,657 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $14,662 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $11,937 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $9,199 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $7,080 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,235 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,639 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,028 |
| Fluticasone Propionate | 59 | $656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $1,354 | $178,724315 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,256 | $47,71896 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,047 | $43,23470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in North Little Rock
- Zafirah SalmanNorth Little Rock$18K
- Dominika SzwedoNorth Little Rock$17K
- Hassan ZebNorth Little Rock$13K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
- Mark SiffordJonesboro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.